19 Einträge gefunden

1. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients

   1. Huebner, Hanna
   2. Häberle, Lothar
   3. Müller, Volkmar
   4. Schrader, Iris
   5. Lorenz, Ralf
   6. Forstbauer, Helmut
   7. Fink, Visnja

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT

   1. Engler, Tobias
   2. Fasching, Peter A
   3. Lüftner, Diana
   4. Hartkopf, Andreas D
   5. Müller, Volkmar
   6. Kolberg, Hans-Christian
   7. Hadji, Peyman

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry

   1. Müller, Volkmar
   2. Hein, Alexander
   3. Hartkopf, Andreas D
   4. Fasching, Peter A
   5. Kolberg, Hans-Christian
   6. Hadji, Peyman
   7. Tesch, Hans

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer - Association With Patient and Disease Characteristics and Effect on Prognosis

   1. Fasching, Peter A
   2. Yadav, Siddhartha
   3. Hu, Chunling
   4. Wunderle, Marius
   5. Häberle, Lothar
   6. Hart, Steven N
   7. Rübner, Matthias

   2021 - Forschungsinformationssystem des UKE
5. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

   1. Hein, Alexander
   2. Hartkopf, Andreas D
   3. Emons, Julius
   4. Lux, Michael P
   5. Volz, Bernhard
   6. Taran, Florin-Andrei
   7. Overkamp, Friedrich

   2021 - Forschungsinformationssystem des UKE
6. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"

   1. Schneeweiss, Andreas
   2. Ettl, Johannes
   3. Lüftner, Diana
   4. Beckmann, Matthias W
   5. Belleville, Erik
   6. Fasching, Peter A
   7. Fehm, Tanja N

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
7. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

   1. Huebner, Hanna
   2. Kurbacher, Christian M
   3. Kuesters, Geoffrey
   4. Hartkopf, Andreas D
   5. Lux, Michael P
   6. Huober, Jens
   7. Volz, Bernhard

   2020 - Forschungsinformationssystem des UKE
8. Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine

   1. Laakmann, Elena
   2. Emons, Julius
   3. Taran, Florin-Andrei
   4. Janni, Wolfgang
   5. Uhrig, Sabrina
   6. Overkamp, Friedrich
   7. Kolberg, Hans-Christian

   2020 - Forschungsinformationssystem des UKE
9. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

   1. Schneeweiss, Andreas
   2. Ettl, Johannes
   3. Lüftner, Diana
   4. Beckmann, Matthias W
   5. Belleville, Erik
   6. Fasching, Peter A
   7. Fehm, Tanja N

   2020 - Forschungsinformationssystem des UKE
10. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

    1. Michel, Laura L
    2. Hartkopf, Andreas D
    3. Fasching, Peter A
    4. Kolberg, Hans-Christian
    5. Hadji, Peyman
    6. Tesch, Hans
    7. Häberle, Lothar

    2020 - Forschungsinformationssystem des UKE
11. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial

    1. de Gregorio, Amelie
    2. Häberle, Lothar
    3. Fasching, Peter A
    4. Müller, Volkmar
    5. Schrader, Iris
    6. Lorenz, Ralf
    7. Forstbauer, Helmut

    2020 - Forschungsinformationssystem des UKE
12. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis

    1. Fasching, Peter A
    2. Hartkopf, Andreas D
    3. Gass, Paul
    4. Häberle, Lothar
    5. Akpolat-Basci, Leyla
    6. Hein, Alexander
    7. Volz, Bernhard

    2019 - Forschungsinformationssystem des UKE
13. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

    1. Lux, Michael P
    2. Nabieva, Naiba
    3. Hartkopf, Andreas D
    4. Huober, Jens
    5. Volz, Bernhard
    6. Taran, Florin-Andrei
    7. Overkamp, Friedrich

    2018 - Forschungsinformationssystem des UKE - frei zugänglich
14. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry

    1. Hartkopf, Andreas D
    2. Huober, Jens
    3. Volz, Bernhard
    4. Nabieva, Naiba
    5. Taran, Florin-Andrei
    6. Schwitulla, Judith
    7. Overkamp, Friedrich

    2018 - Forschungsinformationssystem des UKE
15. Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians

    1. Gass, Paul
    2. Untch, Michael
    3. Müller, Volkmar
    4. Möbus, Volker
    5. Thomssen, Christoph
    6. Häberle, Lothar
    7. Erber, Ramona

    2018 - Forschungsinformationssystem des UKE
16. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry

    1. Müller, Volkmar
    2. Nabieva, Naiba
    3. Häberle, Lothar
    4. Taran, Florin-Andrei
    5. Hartkopf, Andreas D
    6. Volz, Bernhard
    7. Overkamp, Friedrich

    2018 - Forschungsinformationssystem des UKE
17. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial

    1. Jueckstock, Julia
    2. Rack, Brigitte
    3. Friedl, Thomas W P
    4. Scholz, Christoph
    5. Steidl, Julia
    6. Trapp, Elisabeth
    7. Tesch, Hans

    2016 - Forschungsinformationssystem des UKE - frei zugänglich
18. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study

    1. Hein, Alexander
    2. Lambrechts, Diether
    3. von Minckwitz, Gunter
    4. Häberle, Lothar
    5. Eidtmann, Holger
    6. Tesch, Hans
    7. Untch, Michael

    2015 - Forschungsinformationssystem des UKE
19. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors

    1. Nickels, Stefan
    2. Truong, Thérèse
    3. Hein, Rebecca
    4. Stevens, Kristen
    5. Buck, Katharina
    6. Behrens, Sabine
    7. Eilber, Ursula

    2013 - Forschungsinformationssystem des UKE - frei zugänglich